Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Dupilumab as promising treatment for prurigo nodularis: current evidences
By
- AMS
posted
Feb 16, 2021 06:41 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response
- AMS
Added Dec 04, 2020
Blog Entry
Response: Management challenges in prurigo nodularis
- AMS
Added Feb 21, 2020
Blog Entry
Emerging novel therapeutic agents for the treatment of patients with prurigo nodularis
- AMS
Added Jan 04, 2020
Blog Entry
New evidence-based resources to guide treatment of plaque psoriasis
- AMS
Added Sep 08, 2021
Blog Entry
Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes
- AMS
Added Jun 14, 2021
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic